The pharmaceutical industry is undergoing a significant change in how it creates complex molecules, with non-noble-metal catalysis emerging as a powerful tool in process chemistry. Copper-catalyzed cross-coupling reactions (Ullmann-type reactions) are increasingly replacing the well-established palladium-catalyzed alternatives in process chemistry projects at Symeres. Copper, as a catalyst in pharmaceutical synthesis, is considered 30 times less toxic than palladium, according to ICH guidelines,² providing a safer and more sustainable alternative for drug-manufacturing processes due to its lower environmental impact and cost-effective abundance.¹ Additionally, copper catalysis enables the synthesis of valuable compounds without sacrificing reaction efficiency.¹
Our experience in overcoming scaleup challenges and harnessing the benefits of non-noble-metal catalysis makes Symeres the CRO of choice for challenging steps, such as the Ullmann reaction. We are dedicated to enhancing the efficiency, sustainability, and cost-effectiveness of your API manufacturing processes.
Download here
References
- Org. Process Res. Dev. 2022, 26, 1690−1750
- https://www.ich.org/page/quality-guidelines
